Drug intelligence / Profile preview

YOLT-301

Development stage: Preclinical
Lead developer: YolTech Therapeutics
Modality: Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

YOLT-301 is an investigational therapeutic being developed by YolTech Therapeutics for the treatment of hepatitis B. It utilizes in vivo lipid nanoparticle (LNP) delivery technology, suggesting a gene-editing or nucleic acid-based modality. The drug is currently in early research and discovery stages, with its precise mechanism of action and molecular target not yet publicly disclosed. Its development focuses on infectious diseases, specifically hepatitis B[1][2].

Targets

APOE (Apolipoprotein E)LDLR (Low-density lipoprotein receptor)

Beyond the preview

Go deeper on YOLT-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YOLT-301.

Explore the full profile